After 72 h, BIIB021 produced GI50 values of 0.392 ± 0.03 μM in MCF-7, 0.347 ± 0.023 μM in SK-BR-3 and 0.227 ± 0.015 μM in HCT116 cells in an MTT assay. Values were reported as means of two experiments ± SEM. These assay results describe growth inhibition and do not establish a specific cell-death mechanism. [1]
Competitive binding to human Hsp90α
Biochemical assay · Recombinant human Hsp90α N-terminal domain; FITC-geldanamycin competition assay [1]
BIIB021 displaced the fluorescent geldanamycin probe, with a reported IC50 of 0.029 μM. 17-AAG was a reference ligand.
Literature-Reported Treatment Conditions
- Treatment concentration
- Ten-dose series with threefold dilution starting at 100 μM; recombinant protein 30 nM and FITC-GM probe 5 nM.
- Exposure duration
- 30 min compound preincubation; 3 h after probe addition at room temperature.
- Method
- Fluorescence polarization competition assay.
- Vehicle
- Assay buffer contained 1% DMSO; compound stocks delivered in DMSO.
- Reported limits
- Exact SD and individual replicate values not provided. IC50 is assay-dependent and is not a recommended treatment concentration.
Methods and source locations
Compound reported in the paper: BIIB021; Compound label in the paper: BIIB021 reference compound
Evidence for the named BIIB021 molecule under the reported assay conditions; no source-lot equivalence or supplier validation implied.
Section 2.2.1; Table 1, BIIB021 IC50 column and footnote b; Section 3.2.1 (FITC-GM assay)
Competition with FITC-geldanamycin for Hsp90α binding: Fluorescence polarization; mean of two independent experiments; reported SD <20%, exact SD not given. — Table 1, BIIB021 IC50 column and footnote b; Section 3.2.1
Direct binding to the mouse Hsp90α N-terminal domain
Biochemical assay · Isolated mouse Hsp90α N-terminal domain, residues 9–225 [1]
Isothermal titration calorimetry measured direct BIIB021 binding to the isolated domain at 25 °C.
Literature-Reported Treatment Conditions
- Treatment concentration
- Protein in cell: 10–20 μM; BIIB021 in syringe: 200 μM.
- Exposure duration
- 20 injections at 150 s intervals.
- Method
- ITC at 25 °C; buffer-only dilution correction and one-site model; 17-AAG reference ligand.
- Vehicle
- 20 mM Tris, pH 8.0, 100 mM NaCl, up to 2% DMSO.
- Reported limits
- Replicate count and KD uncertainty are not specified for this row. The isolated mouse domain result does not establish cellular potency or isoform selectivity.
Methods and source locations
Compound reported in the paper: BIIB021; Compound label in the paper: BIIB021 reference compound
Evidence for the named BIIB021 molecule under the reported assay conditions; no source-lot equivalence or supplier validation implied.
Section 2.3.1; Table 3, BIIB021 row; Figure 4, BIIB021 panel; Sections 3.3.1 (model identity only) and 3.3.2
Equilibrium binding to mouse Hsp90α N-terminal domain: Isothermal titration calorimetry at 25 °C, buffer-alone dilution subtraction, one-site binding fit. — Table 3, BIIB021 row; Section 3.3.2
Fitted ligand-to-protein binding stoichiometry: One-site fit of ITC data. — Table 3, BIIB021 row; Section 3.3.2
Growth inhibition across three human cancer cell lines
Cell-based study · MCF-7 and SK-BR-3 breast cancer cells; HCT116 colorectal cancer cells [1]
In a 72 h MTT assay, BIIB021 showed submicromolar GI50 values in all three tested cell lines.
Literature-Reported Treatment Conditions
- Exposure duration
- 72 h
- Method
- MTT assay; BIIB021 and 17-AAG were reference compounds in the same cell panel.
- Reported limits
- Exact GI50 concentration series, treatment vehicle and vehicle-control composition are not specified in the selected main-text methods. The separate 10 μM screen is not a recommended concentration.
Methods and source locations
Compound reported in the paper: BIIB021; Compound label in the paper: BIIB021 reference compound
Evidence for the named BIIB021 molecule under the reported assay conditions; no source-lot equivalence or supplier validation implied.
Section 2.2.2; Table 2, BIIB021 row and footnotes a/c; Section 3.2.2
MCF-7 cell growth inhibition: 72 h MTT assay; mean of two experiments ± SEM. — Table 2, BIIB021/MCF-7 GI50 cell and footnote c; Section 3.2.2
SK-BR-3 cell growth inhibition: 72 h MTT assay; mean of two experiments ± SEM. — Table 2, BIIB021/SK-BR-3 GI50 cell and footnote c; Section 3.2.2
HCT116 cell growth inhibition: 72 h MTT assay; mean of two experiments ± SEM. — Table 2, BIIB021/HCT116 GI50 cell and footnote c; Section 3.2.2